FCX vs IKT · P/E 38, rev $13.26B vs $215.2M cap
Freeport-McMoran Copper & Gold Inc (FCX) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
Freeport-McMoran Copper & Gold Inc (FCX) is a copper company listed on US.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported FCX revenue for 2026-06-30 was $13.26B. Net income was $1.86B. FCX currently screens at market cap $67.80B and trailing P/E 38.0.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
FCX currently screens at market cap $67.80B and trailing P/E 38.0. IKT currently screens at market cap $215.2M.
Not investment advice. Open the FCX and IKT stock pages for the full models.
Not investment advice.